Foghorn Therapeutics Inc. Operating Lease, Payments
Foghorn Therapeutics Inc. (FHTX) reported Operating Lease, Payments of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- Foghorn Therapeutics Inc. operating lease, payments for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Foghorn Therapeutics Inc. operating lease, payments for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Foghorn Therapeutics Inc. operating lease, payments for the quarter ending 2025-12-31 was $1.68M, a 37.53% decline year-over-year.
- Foghorn Therapeutics Inc. operating lease, payments for the quarter ending 2025-09-30 was $1.61M, a 40.03% decline year-over-year.
- Foghorn Therapeutics Inc. operating lease, payments for fiscal 2025 was $8.78M, a 18.27% decline from fiscal 2024.
- Foghorn Therapeutics Inc. operating lease, payments for fiscal 2024 was $10.74M, a 5.80% increase from fiscal 2023.
- Foghorn Therapeutics Inc. operating lease, payments for fiscal 2023 was $10.15M, a 1.61% increase from fiscal 2022.
- Foghorn Therapeutics Inc. operating lease, payments for fiscal 2022 was $9.99M, a 2.56% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $1.68M derived: sum of 3 quarters · filed 2026-08-06 | $3.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $1.68M derived: sum of 2 quarters · filed 2026-05-07 | $3.29M derived: sum of 3 quarters · filed 2026-05-07 | $6.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.29M derived: sum of 2 quarters · filed 2026-03-11 | $6.01M derived: sum of 3 quarters · filed 2026-08-06 | $8.78M 10-K · filed 2026-03-11 |
| 2025-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.33M derived: sum of 2 quarters · filed 2026-08-06 | $7.09M 10-Q · filed 2025-11-05 | $9.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.48M 10-Q · filed 2026-08-06 | $8.17M derived: sum of 3 quarters · filed 2026-08-06 | $10.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.76M 10-Q · filed 2026-05-07 | $5.46M derived: sum of 2 quarters · filed 2026-05-07 | $8.14M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $5.38M derived: sum of 2 quarters · filed 2026-03-11 | $10.74M 10-K · filed 2026-03-11 | |
| 2024-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $8.04M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $5.35M 10-Q · filed 2025-08-05 | |||
| 2023-12-31 | $10.15M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $9.99M 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $4.94M derived: sum of 2 quarters · filed 2023-03-09 | $7.37M derived: sum of 3 quarters · filed 2023-03-09 | $9.74M 10-K · filed 2023-03-09 |
| 2021-09-30 | $2.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $4.85M derived: sum of 2 quarters · filed 2021-11-09 | $7.22M 10-Q · filed 2021-11-09 | $8.73M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $4.80M 10-Q · filed 2021-08-10 | $6.31M derived: sum of 3 quarters · filed 2022-08-09 | $6.82M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $2.37M 10-Q · filed 2021-05-11 | $3.89M derived: sum of 2 quarters · filed 2022-08-09 | $4.39M derived: sum of 3 quarters · filed 2022-08-09 | $5.00M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $1.51M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $2.02M derived: sum of 2 quarters · filed 2022-08-09 | $2.63M derived: sum of 3 quarters · filed 2022-08-09 | $3.09M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $507.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.11M derived: sum of 2 quarters · filed 2021-11-09 | $1.57M 10-Q · filed 2021-11-09 | $2.02M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $608.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $1.06M 10-Q · filed 2021-08-10 | $1.51M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | $456.00K 10-Q · filed 2021-05-11 | $907.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $451.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $1.73M 10-K · filed 2021-03-18 | ||
| 2019-09-30 | $1.28M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |